Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target

Monaldi Arch Chest Dis. 2021 May 4;91(2). doi: 10.4081/monaldi.2021.1721.

Abstract

To the Editor COVID-19 (COrona VIrus Disease) patients with cardiovascular (CV) disease, multiple CV risk factors or comorbidities (i.e., arterial hypertension and diabetes) were shown to be more prone to a worse prognosis. SARS-CoV-2 is a still unknown enemy and the role of concomitant cardiovascular therapies has been controversial in the early stages, particularly with regard to Angiotensin-Converting Enzyme inhibitors...

Publication types

  • Letter

MeSH terms

  • COVID-19 / complications
  • COVID-19 / immunology*
  • COVID-19 / mortality
  • COVID-19 / physiopathology
  • Cardiovascular Diseases / complications
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / prevention & control*
  • Deprescriptions
  • Heart Disease Risk Factors*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipidemias / complications
  • Hyperlipidemias / drug therapy*
  • Hypolipidemic Agents / therapeutic use*
  • Primary Prevention
  • SARS-CoV-2
  • Secondary Prevention

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents